Sleep Apnea New Noninvasive Technology Launches Reports Somne

Sleep Apnea New Noninvasie Technology

Sleep Apnea globally statistics show nearly one billion adults aged 30 to 69 years are estimated to have obstructive sleep apnea (OSA).

Somne, a digital health company focused on solving sleep apnea comfortably, announced it is developing a revolutionary non-invasive alternative to CPAP.

“Somne is launching with a desire to have equal focus on patient’s comfort, adherence and efficacy. We’re utilizing variable negative pressure technology to develop this first of its kind medical device which reduces the discomfort that has plagued mass adoption of other sub-optimal products,” said Volha Hrechka, CEO of Somne. “Somne’s novel Class II medical device will be an alternative to CPAP machines and other treatments, with a more comfortable fit.”

“There are millions of people prescribed CPAP for treatment who are simply not using it. Left untreated, OSA can contribute to other serious health complications such as heart problems, high blood pressure, Type 2 diabetes, and cognitive decline,” said Dr. Jerry Kram, a sleep expert, physician, and medical advisor at Somne.  “Somne’s device could be a game-changing, innovative approach for OSA management for sleep apnea patients worldwide.  A comfortable fit from a non-intrusive device will make it easier for patients to embrace treatment.”

Somne’s device for sleep apnea treatment is worn around the neck and uses patented Variable Negative Pressure (vNEP) technology to provide therapy to patients while they sleep. The collar prototype provides gentle suction to prevent the weight of the person’s soft tissue from resting on their airway as they sleep; this keeps the patient’s airway open, assisting them to breathe normally and sleep comfortably.

Recent findings from an IRB-approved human trial of Somne’s prototype device show high efficacy and patient comfort.

Somne continues to work on product development while starting the FDA IDE Application. The company intends to bring its product to market as soon as 2024. To learn more about Somne’s sleep apnea device, visit Somne.co

Consider reading this too.

SourceSomne

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”